Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2016', provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis) - The report reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Vaginal Atrophy (Atrophic Vaginitis) therapeutics and enlists all their major and minor projects - The report assesses Vaginal Atrophy (Atrophic Vaginitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vaginal Atrophy (Atrophic Vaginitis) Overview 6 Therapeutics Development 7 Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview 7 Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies 8 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies 12 Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development 13 EndoCeutics, Inc. 13 Foamix Pharmaceuticals Ltd. 14 Ligand Pharmaceuticals, Inc. 15 Mithra Pharmaceuticals S.A. 16 PEPTONIC medical AB 17 TherapeuticsMD, Inc. 18 Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Estetrol - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 estradiol hemihydrate - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 lasofoxifene tartrate - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 oxytocin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 prasterone - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 TX-004HR - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates 39 Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 44 Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 45 Featured News & Press Releases 45 May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor 45 Apr 02, 2016: TherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy at ENDO 2016 45 Apr 02, 2016: TherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy at ENDO 2016 46 Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study 47 Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting 48 Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting 48 Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting 49 Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause 50 Dec 07, 2015: TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR 51 Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting 52 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 53 Disclaimer 54
List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H1 2016 13 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 14 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 15 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals S.A., H1 2016 16 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H1 2016 17 Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD, Inc., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H1 2016 39 Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2016 44
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
